| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S2213-8587(13)70029-9 |
| P698 | PubMed publication ID | 24622263 |
| P50 | author | Giuseppe Remuzzi | Q16561003 |
| Roberto Trevisan | Q88185989 | ||
| Piero Ruggenenti | Q92877106 | ||
| Flavio Gaspari | Q92877115 | ||
| Aneliya I Parvanova | Q114428690 | ||
| Irene M van der Meer | Q114428727 | ||
| Ariela Benigni | Q41002318 | ||
| Antonio Bossi | Q58920685 | ||
| Annalisa Perna | Q84349157 | ||
| P2093 | author name string | Ilian Iliev | |
| Daglutril in Diabetic Nephropathy Study Group | |||
| P2860 | cites work | Avosentan reduces albumin excretion in diabetics with macroalbuminuria | Q24642372 |
| Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies | Q24658205 | ||
| Cardiorenal end points in a trial of aliskiren for type 2 diabetes | Q28278569 | ||
| Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy | Q29615215 | ||
| A novel potent vasoconstrictor peptide produced by vascular endothelial cells | Q29620540 | ||
| Towards triple vasopeptidase inhibitors for the treatment of cardiovascular diseases. | Q30364697 | ||
| Avosentan for overt diabetic nephropathy | Q33702404 | ||
| An update on: cardiovascular and respiratory changes during sleep in normal and hypertensive subjects. | Q33869939 | ||
| Clinical practice. Nephropathy in patients with type 2 diabetes | Q34123307 | ||
| Preventing microalbuminuria in type 2 diabetes | Q34552302 | ||
| Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy | Q34726905 | ||
| New therapeutics that antagonize endothelin: promises and frustrations | Q35013988 | ||
| Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. | Q35534210 | ||
| Treatment of isolated systolic hypertension in diabetes mellitus type 2. | Q36507647 | ||
| Role of endothelin-1 in clinical hypertension: 20 years on. | Q37234843 | ||
| The RAAS in the pathogenesis and treatment of diabetic nephropathy | Q37741783 | ||
| The "J curve" problem revisited: old and new findings | Q37762755 | ||
| Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins | Q41267402 | ||
| Atrial natriuretic peptide and prostacyclin synergistically mediate hyperfiltration and hyperperfusion of diabetic rats | Q41790822 | ||
| The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators | Q42544459 | ||
| A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial | Q43277549 | ||
| Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases | Q43593878 | ||
| Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes | Q43928942 | ||
| Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). | Q44242786 | ||
| Inhibition of both neutral endopeptidase and endothelin-converting enzyme by SLV306 reduces proteinuria and urinary albumin excretion in diabetic rats | Q46444171 | ||
| Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document | Q56970676 | ||
| Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study | Q57085479 | ||
| Vasopeptidase inhibition and angio-oedema | Q74252375 | ||
| Atrial natriuretic peptide increases urinary albumin excretion in people with normoalbuminuric type-2 diabetes | Q80258843 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | placebo | Q269829 |
| type 2 diabetes | Q3025883 | ||
| P304 | page(s) | 19-27 | |
| P577 | publication date | 2013-06-13 | |
| P1433 | published in | The Lancet: Diabetes & Endocrinology | Q27725107 |
| P1476 | title | Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial | |
| P478 | volume | 1 |
| Q38225794 | Current state of endothelin receptor antagonism in hypertension and pulmonary hypertension |
| Q36441616 | Diabetic nephropathy: What does the future hold? |
| Q38373858 | Drug therapy for the patient with resistant hypertension |
| Q26752292 | Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease |
| Q35984860 | Effects of endopeptidase inhibition on the relaxation response of isolated human penile erectile tissue to vasoactive peptides. |
| Q26767156 | Endothelin |
| Q35182125 | Endothelin A receptor antagonist, atrasentan, attenuates renal and cardiac dysfunction in Dahl salt-hypertensive rats in a blood pressure independent manner |
| Q34437692 | Endothelin and endothelin antagonists in chronic kidney disease |
| Q28246158 | Endothelin@25 - new agonists, antagonists, inhibitors and emerging research frontiers: IUPHAR Review 12 |
| Q64443714 | Endothelins in cardiovascular biology and therapeutics |
| Q90046724 | New Molecules for Treating Resistant Hypertension: a Clinical Perspective |
| Q38429870 | New developments in the pharmacological treatment of hypertension: dead-end or a glimmer at the horizon? |
| Q37620461 | Novel approaches for treating hypertension |
| Q39170387 | Novel avenues for treating diabetic nephropathy: new investigational drugs. |
| Q38265818 | Novel effective drugs for diabetic kidney disease? or not? |
| Q30374407 | Pleiotropic effects of type 2 diabetes management strategies on renal risk factors. |
| Q34472913 | Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials |
| Q38269052 | The role of endothelin-1 in pulmonary arterial hypertension |
| Q38678678 | Therapeutic potential of endothelin receptor antagonism in kidney disease |
Search more.